{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T22:28:48Z","timestamp":1785018528528,"version":"3.55.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>We evaluated the health-related quality of life (HRQoL) benefits of upadacitinib (UPA) induction and maintenance treatment in a phase 3 study of patients with ulcerative colitis (UC) across a broad range of patient-centered outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients received UPA 45 mg once daily or placebo as induction treatment for 8 weeks. Patients who achieved clinical response were rerandomized to receive once daily UPA 15 mg, 30 mg, or placebo as maintenance treatment for 52 weeks. The percentages of patients reporting a clinically meaningful within-person change from baseline in the Ulcerative Colitis Symptoms Questionnaire, Inflammatory Bowel Disease Questionnaire, Work Productivity and Impairment Questionnaire, 36-Item Short Form Survey, and European Quality of Life-5 Dimension 5 Levels were evaluated at weeks 2 and 8 of induction and at weeks 0 and 52 of maintenance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Significant improvements from baseline in all HRQoL measures except the Work Productivity and Impairment Questionnaire\u2013absenteeism were achieved with UPA (P\u2005&amp;lt;\u2005.001) vs placebo as early as week 2 of induction. These improvements were sustained at week 52 with significantly more patients treated with either 15 mg or 30 mg UPA vs placebo achieving meaningful within-person change in the Ulcerative Colitis Symptoms Questionnaire; Inflammatory Bowel Disease Questionnaire; overall work impairment, presenteeism, and activity impairment; both 36-Item Short Form Survey Physical and Mental Component Summaries; and European Quality of Life-5 Dimension 5 Levels (P\u2005&amp;lt;\u2005.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Induction treatment with UPA 45 mg significantly improved HRQoL measures. A significantly higher percentage of patients who responded to induction treatment with UPA maintained clinically meaningful improvements consistently across a wide range of HRQoL outcomes after 52 weeks of maintenance therapy with UPA (15 mg and 30 mg) compared with placebo. (ClinicalTrials.gov, Numbers: NCT02819635, NCT03653026).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izac260","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T11:01:36Z","timestamp":1673866896000},"page":"1421-1430","source":"Crossref","is-referenced-by-count":19,"title":["Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4971-6902","authenticated-orcid":false,"given":"Julian","family":"Pan\u00e9s","sequence":"first","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Hospital Cl\u00ednic de Barcelona, IDIBAPS, CIBERehd , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Edward V","family":"Loftus","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D R","family":"Higgins","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Michigan , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James O","family":"Lindsay","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Royal London Hospital, Barts Health NHS Trust , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhou","sequence":"additional","affiliation":[{"name":"AbbVie Inc , North Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Yao,","sequence":"additional","affiliation":[{"name":"AbbVie Inc , North Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dapo","family":"Ilo","sequence":"additional","affiliation":[{"name":"AbbVie Inc , North Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Phillips","sequence":"additional","affiliation":[{"name":"AbbVie Inc , North Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinda","family":"Tran","sequence":"additional","affiliation":[{"name":"AbbVie and the Comparative Health Outcomes, Policy, and Economics Institute, University of Washington , Seattle, WA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Sanchez Gonzalez","sequence":"additional","affiliation":[{"name":"AbbVie Inc , North Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Vermeire","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,16]]},"reference":[{"issue":"9853","key":"2023090111594064900_CIT0001","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","article-title":"Ulcerative colitis","volume":"380","author":"Ord\u00e1s","year":"2012","journal-title":"Lancet"},{"issue":"10080","key":"2023090111594064900_CIT0002","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"2023090111594064900_CIT0003","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.cgh.2016.10.039","article-title":"Incidence and prevalence of Crohn\u2019s disease and ulcerative colitis in Olmsted County, Minnesota from 1970 through 2010","volume":"15","author":"Shivashankar","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2023090111594064900_CIT0004","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/j.gastro.2016.10.020","article-title":"Understanding and preventing the global increase of inflammatory bowel disease","volume":"152","author":"Kaplan","year":"2017","journal-title":"Gastroenterology"},{"issue":"7","key":"2023090111594064900_CIT0005","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.dld.2021.03.002","article-title":"Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: a narrative review","volume":"53","author":"Armuzzi","year":"2021","journal-title":"Dig Liver Dis."},{"issue":"7","key":"2023090111594064900_CIT0006","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.crohns.2013.11.017","article-title":"Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross-sectional, observational study","volume":"8","author":"Gibson","year":"2014","journal-title":"J Crohns Colitis"},{"issue":"6","key":"2023090111594064900_CIT0007","doi-asserted-by":"crossref","first-page":"874","DOI":"10.14309\/ajg.0000000000000183","article-title":"A treat-to-target update in ulcerative colitis: a systematic review","volume":"114","author":"Ungaro","year":"2019","journal-title":"Am J Gastroenterol."},{"issue":"5","key":"2023090111594064900_CIT0008","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1053\/j.gastro.2020.10.065","article-title":"Selecting end points for disease-modification trials in inflammatory bowel disease: the SPIRIT consensus from the IOIBD","volume":"160","author":"Le Berre","year":"2021","journal-title":"Gastroenterology"},{"issue":"5","key":"2023090111594064900_CIT0009","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"issue":"9","key":"2023090111594064900_CIT0010","first-page":"CD008655","article-title":"The impact of biological interventions for ulcerative colitis on health-related quality of life","volume":"9","author":"LeBlanc","year":"2015","journal-title":"Cochrane Database Syst Rev."},{"issue":"6","key":"2023090111594064900_CIT0011","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn\u2019s disease: results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Pan\u00e9s","year":"2017","journal-title":"Gut"},{"key":"2023090111594064900_CIT0012","doi-asserted-by":"crossref","first-page":"S737","DOI":"10.1093\/ecco-jcc\/jjz202","article-title":"Efficacy of JAK inhibitors in ulcerative colitis","volume":"14","author":"Ferrante","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2023090111594064900_CIT0013","doi-asserted-by":"crossref","first-page":"ii45","DOI":"10.1093\/rheumatology\/keaa896","article-title":"JAK1 inhibition and inflammatory bowel disease","volume":"60","author":"Harris","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"2023090111594064900_CIT0014","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"issue":"12","key":"2023090111594064900_CIT0015","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1093\/ecco-jcc\/jjab099","article-title":"Upadacitinib treatment improves symptoms of bowel urgency and abdominal pain, and correlates with quality of life improvements in patients with moderate to severe ulcerative colitis","volume":"15","author":"Ghosh","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"6","key":"2023090111594064900_CIT0016","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1136\/gut.2004.056358","article-title":"Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis","volume":"54","author":"Higgins","year":"2005","journal-title":"Gut"},{"issue":"2","key":"2023090111594064900_CIT0017","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0016-5085(94)90585-1","article-title":"Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn\u2019s Relapse Prevention Trial Study Group","volume":"106","author":"Irvine","year":"1994","journal-title":"Gastroenterology"},{"issue":"4","key":"2023090111594064900_CIT0018","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00054725-199712000-00004","article-title":"An evaluation of utility measurement in Crohn\u2019s disease","volume":"3","author":"Gregor","year":"1997","journal-title":"Inflamm Bowel Dis."},{"issue":"2","key":"2023090111594064900_CIT0019","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.clinthera.2008.02.016","article-title":"Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn\u2019s disease","volume":"30","author":"Reilly","year":"2008","journal-title":"Clin Ther."},{"issue":"5","key":"2023090111594064900_CIT0020","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics."},{"key":"2023090111594064900_CIT0021","doi-asserted-by":"crossref","first-page":"S472","DOI":"10.14309\/00000434-200709002-00962","article-title":"Minimally important difference for WPAI:CD scores: defining relevant impact on work productivity in active Crohn\u2019s disease: 962","volume":"102","author":"Sandborn","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"2023090111594064900_CIT0022","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s41687-018-0088-8","article-title":"Psychometric validation of the work productivity and activity impairment questionnaire in ulcerative colitis: results from a systematic literature review","volume":"2","author":"Yarlas","year":"2018","journal-title":"J Patient Rep Outcomes"},{"issue":"24","key":"2023090111594064900_CIT0023","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1097\/00007632-200012150-00008","article-title":"SF-36 health survey update","volume":"25","author":"Ware","year":"2000","journal-title":"Spine"},{"issue":"6","key":"2023090111594064900_CIT0024","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-Item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care."},{"issue":"9","key":"2023090111594064900_CIT0025","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/j.1365-2036.2009.03966.x","article-title":"Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn\u2019s disease","volume":"29","author":"Coteur","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"2023090111594064900_CIT0026","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s11136-012-0322-4","article-title":"Measurement properties of the EQ-5D-5L compared with the EQ-5D-3L across eight patient groups: a multi-country study","volume":"22","author":"Janssen","year":"2013","journal-title":"Qual Life Res"},{"issue":"1","key":"2023090111594064900_CIT0027","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ibd.20989","article-title":"Validity, reliability, and responsiveness of the EQ-5D in inflammatory bowel disease in Germany","volume":"16","author":"Stark","year":"2010","journal-title":"Inflamm Bowel Dis."},{"issue":"8","key":"2023090111594064900_CIT0028","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.cgh.2013.10.019","article-title":"Evaluation of the patient-reported outcomes measurement information system in a large cohort of patients with inflammatory bowel diseases","volume":"12","author":"Kappelman","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2023090111594064900_CIT0029","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11739-019-02268-0","article-title":"Stigmatisation and resilience in inflammatory bowel disease","volume":"15","author":"Lenti","year":"2020","journal-title":"Intern Emerg Med."},{"issue":"5","key":"2023090111594064900_CIT0030","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00535-016-1241-x","article-title":"Impact of inflammatory bowel disease on Japanese patients\u2019 quality of life: results of a patient questionnaire survey","volume":"52","author":"Ueno","year":"2017","journal-title":"J Gastroenterol."},{"issue":"6","key":"2023090111594064900_CIT0031","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s11136-008-9362-1","article-title":"Beyond standard quality of life measures: the subjective experiences of living with inflammatory bowel disease","volume":"17","author":"Wolfe","year":"2008","journal-title":"Qual Life Res"},{"issue":"3","key":"2023090111594064900_CIT0032","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/apt.16445","article-title":"Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents","volume":"54","author":"van Linschoten","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"2023090111594064900_CIT0033","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/ecco-jcc\/jjab029","article-title":"The burden of inflammatory bowel disease in Europe in 2020","volume":"15","author":"Zhao","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"4","key":"2023090111594064900_CIT0034","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1572-0241.2007.01094.x","article-title":"The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients","volume":"102","author":"Feagan","year":"2007","journal-title":"Am J Gastroenterol."},{"issue":"2","key":"2023090111594064900_CIT0035","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/apt.13852","article-title":"Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial","volume":"45","author":"Feagan","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2023090111594064900_CIT0036","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"issue":"2","key":"2023090111594064900_CIT0037","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/ecco-jcc\/jjx133","article-title":"Tofacitinib in patients with ulcerative colitis: health-related quality of life in phase 3 randomised controlled induction and maintenance studies","volume":"12","author":"Pan\u00e9s","year":"2018","journal-title":"J Crohns Colitis"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izac260\/48723898\/izac260.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/29\/9\/1421\/51317400\/izac260.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/29\/9\/1421\/51317400\/izac260.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T12:56:15Z","timestamp":1693572975000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/29\/9\/1421\/6988017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,16]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,1,16]]},"published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izac260","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,1]]},"published":{"date-parts":[[2023,1,16]]}}}